<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838509</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI034</org_study_id>
    <nct_id>NCT04838509</nct_id>
  </id_info>
  <brief_title>Diagnoses Associated With Persistent Elevation of Creatine Kinase</brief_title>
  <official_title>Diagnoses Associated With Persistent Elevation of Creatine Kinase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum creatinine kinase (CK) level varies with age, gender, race and physical activity. For&#xD;
      these reasons there is no normal serum CK level. Many pathological situations cause&#xD;
      hyperCKemia, such as neuromuscular disorders (muscular dystrophy, inflammatory myositis,&#xD;
      mitochondrial myopathy) and multiple systemic causes. The diagnostic approach to pauci or&#xD;
      asymtomatic hyperCKemia can therefore be difficult and lead to multiple, and sometimes&#xD;
      invasive tests, such as muscle biopsy. This study aims to describe the diagnoses associated&#xD;
      with persistent elevation of serum creatine kinase and to precise the role of the muscule&#xD;
      biopsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Actual">June 24, 2021</completion_date>
  <primary_completion_date type="Actual">June 24, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis</measure>
    <time_frame>at the end of all investigations, an average of 12 months</time_frame>
    <description>The final diagnosis, as written in the medical record at the end of the investigations in the ward of internal medicin, responsible for the elevation of creatine kinase between: inflammatory myositis, mitochondrial myopathy, muscular dystrophy, non neuromuscular pathology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle biopsy</measure>
    <time_frame>at the end of all investigations, an average of 12 months</time_frame>
    <description>Among the patients who underwent a muscle biopsy, number of anormal biopsies that contributed to make the final diagnosis responsible of the elevation of creatine kinase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical presentation</measure>
    <time_frame>at the end of all investigations, an average of 12 months</time_frame>
    <description>association between the initial clinical presentation and the final diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paraclinical presentation</measure>
    <time_frame>at the end of all investigations, an average of 12 months</time_frame>
    <description>association between the initial paraclinical presentation and the final diagnosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">148</enrollment>
  <condition>Creatine Kinase</condition>
  <condition>Muscular Diseases</condition>
  <arm_group>
    <arm_group_label>Patients with elevated creatine kinase</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>retrospective descriptive without intervention</description>
    <arm_group_label>Patients with elevated creatine kinase</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalised in the ward of internal medicin of Nancy University Hospital or UNEOS&#xD;
        General Hospital of Metz between 2009 and 2018.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients hospitalised in a ward of internal medicin&#xD;
&#xD;
          -  having a persistent elevation of serum creatine kinase &gt;3 times the upper normal&#xD;
             laboratory value, repeated for 2 times&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known neuro-muscular disease causing elevation of creatine kinase&#xD;
&#xD;
          -  evident post-traumatic cause responsible for the elevation of creatine kinase&#xD;
&#xD;
          -  incomplete medical records&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Lev VOLKOV</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Creatine Kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

